| Filed On | Filing |
|---|---|
| 15 Sep 2026 |
8-K: Regulation FD Disclosure
Predictive Wound Healing AI + Multispectral Imaging = Faster, More Accurate Treatment Decisions in Healthcare Nasdaq: MDAI September 2026 1 |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Company Continues to Advance Towards First Commercial Sales of |
| 08 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Spectral AI, Inc. (the “Company”) is pleased to make an offer of employment as Chief Commercial Officer, subject to the terms set forth in this letter (the “Letter”), with an anticipated start date of July 31, 2026 (the “Start Date”), pe... |
| 01 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure
DALLAS, TX – June 1, 2026 - Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today a... |
| 26 May 2026 |
8-K: Regulation FD Disclosure
DALLAS, TX - May 26, 2026 - Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today a... |
| 22 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Spectral MD, Inc. (the “Company”) is pleased to make an offer of employment to you on the terms set forth in this letter (the “Letter”), with a start date on February 9, 2026 (the “Effective Date”). The terms of your position with the Co... |
| 08 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Spectral AI, Inc. (the “Company”) is pleased to make an offer of employment to you as the Chief Financial Officer of the Company, subject to the terms set forth in this letter (the “Letter”), with an anticipated start date of May 4, 2026... |
| 25 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Full Year Research & Development Revenue of $19.7 Million; Q4 2025 Revenue of $3.8 Million |
| 20 Mar 2026 |
8-K: Regulation FD Disclosure
DALLAS, TX – March 18, 2026 - Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today... |
| 10 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
DALLAS, TX – February 10, 2026 - Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, to... |
| 03 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
(b) Today, the Company announced that on February 1, 2026, Mr. Jeremiah Sparks announced that he was stepping down as the Company’s Chief Commercial Officer to pursue other opportunities. Mr. Sparks’ departure was not the result of any d... |
| 06 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On January 5, 2026, Colin Bristow tendered his resignation as a director on the Board of Directors of the Company, with such resignation becoming effective immediately. Mr. Bristow’s resignation was not the result of any disagreement wit... |
| 24 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This Securities Purchase Agreement (this “Agreement”) is dated as of October 22, 2025, between Spectral AI, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its su... |
| 13 Aug 2025 |
8-K: Results of Operations and Financial Condition
Research & Development Revenue of $5.1 Million, total revenue for the first half of 2025 of $11.8 Millon |
| 30 Jun 2025 |
8-K: Regulation FD Disclosure
DALLAS, TX – June 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administr... |
| 03 Jun 2025 |
8-K: Changes in Registrant's Certifying Accountant
We were previously principal accountants for Spectral AI, Inc. (the Company) and, under the date of March 31, 2025, we reported on the consolidated financial statements of the Company as of and for the years ended December 31, 2024 and 2... |
| 30 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
DALLAS, TX - May 30, 2025 - Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today a... |
| 29 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure
DALLAS, TX - May 29, 2025 - Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announc... |
| 14 May 2025 |
8-K: Results of Operations and Financial Condition
Improved Capital Structure Reflected in Cash of $14.1 Million |
| 02 Apr 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Spectral AI Announces 2024 Fourth Quarter and Full Year Financial Results 2024 Research & Development Revenue of $30 Million |
Loading...